Evidence map›Paper›PMID 41938518›Full record

ArticleInternational journal of medical sciences2026

Longitudinal Radiological Remodeling after Irreversible Electroporation Versus Radiofrequency Ablation: A Prospective Comparative Study (The LIRA Study).

Yiting Liu, Qin Liu, Haiyang Yu, Wei Huang, Ziyin Wang, Qingbing Wang, Jingjing Liu, Xiaoyan Fei, Junwei Gu, Zhongmin Wang and 2 more

Abstract readComparative Study
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yiting LiuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Qin LiuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Haiyang YuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Wei HuangDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Ziyin WangDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Qingbing WangDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Jingjing LiuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Xiaoyan FeiDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Junwei GuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Zhongmin WangDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Xiaoyi DingDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.
Zhiyuan WuDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To evaluate the short- to intermediate-term radiological evolution of ablation zones using contrast-enhanced MRI and to assess clinically relevant outcomes following irreversible electroporation (IRE) and radiofrequency ablation (RFA) in patients with liver tumors. Methods: Thirty-five ablation zones from 24 patients were prospectively evaluated in the LIRA Study. Serial contrast-enhanced MRI was performed at predefined time points (post-ablation day 7 as baseline, 1 month, and 3 months), and ablation-zone geometry was quantitatively analyzed and compared between groups. In addition to longitudinal radiological evolution of the ablation zone, local recurrence-free survival (LRFS) was evaluated as the primary clinical endpoint; disease control and treatment-related safety were also assessed. Peripheral immune profiling was assessed in an exploratory manner. Results: Longitudinal imaging demonstrated distinct ablation-zone remodeling patterns between the two modalities. Ablation-zone volume and surface area decreased significantly at both 1 and 3 months in both groups, with smaller normalized values in the IRE group. In contrast, a significantly greater change in the surface area-to-volume ratio was observed only at 3 months with IRE versus RFA (IRE: 0.27 [0.16-0.36] vs. RFA: 0.04 [0.02-0.08]; Conclusions: IRE is associated with more pronounced longitudinal radiological evolution of the ablation zone compared with RFA, with comparable clinical outcomes and time-dependent immune fluctuations observed after ablation in liver tumors.

Indexed as

Carcinoma, HepatocellularIrreversible Electroporation TherapyLiver NeoplasmsNeoplasm Recurrence, LocalRadiofrequency AblationAgedContrast MediaFemaleHumansLiverMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesTreatment OutcomeContrast Mediaablation zoneirreversible electroporationliver tumorslocal tumor controlradiofrequency ablationradiological evolution

Identifiers

PMID41938518
PMCPMC13048883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.